SCHEMBL5507438

SCHEMBL5507438

COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 17/20 1.00
DRD2 P14416 16/20 1.00
DRD4 P21917 11/20 1.00
HTR1A P08908 7/20 1.00
ADRA1D P25100 7/20 1.00
ADRA1A P35348 7/20 1.00
ADRA1B P35368 7/20 1.00
DRD1 P21728 6/20 1.00
HTR2A P28223 5/20 1.00
HTR2C P28335 4/20 1.00
HTR2B P41595 4/20 1.00
ADRA2A P08913 2/20 0.69
MEN1 O00255 1/20 0.69
LMNA P02545 1/20 0.69
TP53 P04637 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2D6 P10635 1/20 0.69
TSHR P16473 1/20 0.69
NFKB1 P19838 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13094475 0.85 DRD3 (1.00) DRD3DRD2DRD4HTR1AADRA1D
SCHEMBL9653810 0.84 DRD2 (0.93) DRD3DRD2DRD4HTR1AADRA1D
SCHEMBL30298994 0.83 DRD3 (1.00) DRD3DRD2DRD4HTR1AADRA1D
SCHEMBL9650843 0.83 ADRA1D (1.00) DRD3DRD2DRD4HTR1AADRA1D
Bp-897 SCHEMBL2125882 0.82 DRD2 (1.00) DRD3DRD2DRD4HTR1AADRA1D
Bp-897 SCHEMBL30027453 0.82 DRD2 (1.00) DRD3DRD2DRD4HTR1AADRA1D
Bp-897 SCHEMBL29382551 0.82 DRD2 (1.00) DRD3DRD2DRD4HTR1AADRA1D
SCHEMBL7561768 0.81 DRD2 (0.94) DRD3DRD2DRD4HTR1AADRA1D
SCHEMBL14761722 0.81 DRD2 (1.00) DRD3DRD2DRD4HTR1AADRA1D
Hydrochloric Acid SCHEMBL7595382 0.80 DRD2 (0.94) DRD3DRD2DRD4HTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1749529-A1 Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases SCHWARZ PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1733727-A1 Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders SCHWARZ PHARMA AG (DE) 2006-12-20 EP disclosed